Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response
Introduction
Pancreatic ductal adenocarcinoma (PDA) represents a therapeutic challenge due to its lack of responsiveness to current treatments and its poor prognosis. Unfortunately, the five-year survival rate of patients with pancreatic cancer has not significantly improved over the last two decades and remains as low as under 10% (NIH surveillance, epidemiology, and end results program) which stems from difficulties in early detection, adjacency to major vessels, and poor response rates to cytotoxic drugs. Although traditional cytotoxic drug therapy and radiotherapy do not have satisfying results, FOLFIRINOX and nab-paclitaxel have recently shown improved survival and response rates in randomized control studies [1,2]. In addition, newly developed target agents and immunologic drugs have raised the expectation of a treatment response to PDA. For the evaluation of such drugs, appropriate ex vivo models are needed to accurately represent the complex and heterogeneous in vivo tumor biology and pathology of tumors. However, there has not yet been a proper ex vivo platform to predict an individual's response to drugs.
Current ex vivo tumor models including primary cell lines, xenografts, or genetically engineered mice (GEM) have been actively used to test tumor biology and drug response. However, these models are inherently limited by an absence of stroma and low heterogeneity. PDA characteristically has abundant stroma that is considered to play a major role in tumor growth and drug resistance [3,4]. On the other hand, organotypic slice cultures preserve the stromal microenvironment as well as tumor cells, which leads to the maintenance of the tumor-stroma interaction. Recently, organotypic slice cultures have been developed and studied in several tumors, such as head, neck, gastric, and breast tumors [[5], [6], [7], [8]]. In addition to preserving the tumor-stroma interaction, organotypic slice culture models allow the rapid assessment of drugs requiring only a few days and may serve to find drugs tailored to individual patients. Because different tumor entities display distinct growth and culture characteristics, careful consideration of slice preparation and culture conditions suitable for PDA is needed. A recent study that included JH Chang as a coauthor established a PDA slice culture model and demonstrated its usefulness for immune microenvironment research [9]. We aimed to reproduce this precision-cut organotypic slice culture model from human PDA and to evaluate the responses of PDA slices to established cytotoxic drugs compared to the response of PDA cell lines.
Section snippets
Patients and cell lines
A total of 10 pancreatic tumor specimens were collected during surgery from patients who underwent surgery for pancreatic cancer. Details regarding the patients and surgery information are described in Table 1. Six patients underwent Whipple's operation, two underwent pylorus-preserving pancreaticoduodenectomy (PPPD), one underwent distal pancreatectomy, and one underwent radical antegrade modular pancreato-splenectomy (RAMPS). The final stages of pancreatic cancer according to the 8th edition
Gross morphologies and surface areas of tumor slices were preserved during slice culture
The gross morphology of each PDA slice showed a rectangular shape, and this shape did not change during culture (Fig. 1A). The size of the tumor slices did not grossly change for the first few days of culture but tended to gradually decrease. The surface areas of the tumor slices were compared based on their culture day, as shown in Fig. 1B. The mean slice surface areas (n = 10) on each culture day compared that on day 0 were 89.6% (day 1), 79.0% (day 3), 68.6% (day 5), 55.2% (day 7), and 47.0%
Discussion
Conventional evaluation models for anti-tumor therapeutic agents, such as primary cell lines and tumor xenografts, are limited in their representations of human PDA. Primary cell lines are derived from fast-growing tumor cells during cultivation and do not contain stroma, which result in the absences of tumor-stroma interactions and tumor heterogeneity. Although the mouse tumor xenograft model retains the tumor microenvironment, it is within the murine stroma and the mouse is an
Conflicts of interest
The authors declare no competing financial interest.
Acknowledgments
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2016R1D1A1B03931040) and supported by the Institute of Clinical Medicine Research of Bucheon St. Mary's Hospital (Research Fund, BCMC17LH03). We acknowledge Dr. Xiuyun Jiang and Prof. Venu G. Pillarisetty of the Department of Surgery, University of Washington for supporting the concept and design of our experiment.
References (20)
- et al.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
N Engl J Med
(2011) - et al.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
N Engl J Med
(2013) - et al.
Stromal fibroblasts in cancer: a novel tumor-promoting cell type
Cell Cycle
(2006) - et al.
Pancreatic adenocarcinoma
N Engl J Med
(2014) - et al.
Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance
Br J Canc
(2014) - et al.
Organotypic slice cultures of human gastric and esophagogastric junction cancer
Canc Med
(2016) - et al.
Tumor slice culture system to assess drug response of primary breast cancer
BMC Canc
(2016) - et al.
The practicalities of using tissue slices as preclinical organotypic breast cancer models
J Clin Pathol
(2013) - et al.
Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment
OncoImmunology
(2017) - et al.
Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices
World J Gastroenterol
(2009)
Cited by (29)
Patient-derived tumor models in cancer research: Evaluation of the oncostatic effects of melatonin
2023, Biomedicine and PharmacotherapyNew local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model
2022, Biomedicine and PharmacotherapyCitation Excerpt :In addition, leiomyomas are quite heterogeneous tumors, with a variable number of cells and fibrous connective tissue, which lead to different tumor stiffness. Despite this, the percentage of dead cells after seven days of culture ranged from 10% to 28% in the tissue area under study, in agreement with previous reports in ex vivo cancer cultures, such as breast, pancreas, colon and lung carcinomas [42–44]. Interestingly, this initial cell death increased drastically after ex vivo incubation with ganirelix, both supplemented in the culture media or released from PLGA-microspheres.
Temporal single-cell regeneration studies: the greatest thing since sliced pancreas?
2021, Trends in Endocrinology and MetabolismCitation Excerpt :The enhanced anatomical features of slices generated in this manner has enabled research of ever-increasing complexity, including the dynamic study of islet physiology [54]; patch-clamp [55] and calcium imaging [56]; the functional analysis of islet pericytes [57] and macrophages [58]; ductal [59] and acinar [60] cell biology and function; and, in general, the exploration of the nuanced interactions between islets, blood vessels [61], neural networks [62], and the immune system [63] (Figure 1). Research on these areas has been recently expanded to encompass samples from type 1 and 2 diabetes patients [64–66], as well as pancreatic ductal adenocarcinoma [63,67], which has opened the door to the study of pancreatic disease in an in vitro setting closely resembling the real organ. Importantly, viable/functional human slices can be shipped from centralized procurement centers, which has made this valuable model available to laboratories around the world.
Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
2021, Advanced Drug Delivery ReviewsCitation Excerpt :In 1985, Smith et al. introduced the use of “precision-cut” tissue slices obtained from PDAC patients, which, as the name implies, are cut in with well-defined parameters to be used for drug screening in vitro [51]. Precision-cut slices allow for the evaluation of therapeutics in a biological-relevant context, which consists of the tumor cells, the respective TME components, vasculature and the ECM [52–55]. Recently, Misra et al. demonstrated the use of precision-cut PDAC tissue slices in a laboratory setting [56].
Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
2023, Langenbeck's Archives of SurgeryCulture of vibrating microtome tissue slices as a 3D model in biomedical research
2023, Journal of Biological Engineering